HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program
Abstract
No abstract availableKeywords
Funding Information
- Roche Products Pty Limited
This publication has 33 references indexed in Scilit:
- HER2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?Diagnostic Cytopathology, 2014
- Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an A sia‐ P acific T ask F orceAsia-Pacific Journal of Clinical Oncology, 2014
- Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With TrastuzumabJournal of Clinical Oncology, 2013
- Prognostic Role of Human Epidermal Growth Factor Receptor in Gastric Cancer: A Systematic Review and Meta-analysisArchives of Medical Research, 2013
- HER2-positive gastric cancerGastric Cancer, 2013
- Global estimates of cancer prevalence for 27 sites in the adult population in 2008International Journal of Cancer, 2012
- HER2 testing in gastric cancer: a practical approachLaboratory Investigation, 2012
- Gastric HER2 Testing Study (GaTHER)American Journal of Surgical Pathology, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patientsBritish Journal of Cancer, 2009